{
  "docId": "019de075-6448-707d-82ec-cbbeebb7feb3",
  "docSlug": "1eef6abd03697885c8a70f789c554a37",
  "documentTitle": "Nuvectis Pharma | Investor Presentation Deck | 23 slides",
  "authorId": "nuvectis-pharma",
  "authorName": "Nuvectis Pharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 23,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-6448-707d-82ec-cbbeebb7feb3/14",
  "deckHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3",
  "deckJsonHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3.json",
  "deckAnchorHref": "/decks/019de075-6448-707d-82ec-cbbeebb7feb3#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.415
      },
      "kind": "list",
      "text": "Differentiated Features: Highly selective - Lack of immunosuppression; Unique mechanism of action - Complete shut-down of the SRC pathway by scaffold and catalytic domain inactivation; Ability to cross the blood-brain-barrier",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "146cb6fe-ea25-4f8f-9a33-d9eccca2c34a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.94,
        "x": 0.03,
        "y": 0.775
      },
      "kind": "list",
      "text": "Phase 1 Program: IND cleared; Phase 1a clinical trial expected to begin in 3Q2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65c06dc0-c69c-41b3-870c-fdb7afdad2a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.235
      },
      "kind": "list",
      "text": "Precision Medicine Approach: Discovered at the University of Edinburgh, Scotland; A potent, novel, small molecule inhibitor of YES1/SRC signaling; YES1-Hippo pathway alteration associated with sensitivity to NXP900 in squamous cell models",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9cd33e71-fe94-4fcb-97d6-069cd1e22ed3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.595
      },
      "kind": "list",
      "text": "Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib (2022 paper); Ability to reverse resistance to enzalutamide in mCRPC (2023 paper)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faf5791f-0824-4337-96e0-2fc724c9f73b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.43,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "NXP900 Key Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31d7ad25-de76-4ce2-a7b2-20e5b71eece7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "fad52c2c-47f2-4029-9495-5f8cb61d0844",
      "evidence": "list/bullet: Strong Preclinical Proof of Concept: POC in multiple xenograft models – significant single-agent activity in squamous cell cancer models; Ability to re-sensitize resistant NSCLC cells to osimertinib (2022 pa",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}